Price
Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.
Smart Score
Top tierAurinia is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. In January 2021, the Company introduced LUPKYNIS® (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis (“LN”). Aurinia is also developing aritinercept, a dual inhibitor of B cell-activating factor (“BAFF”) and a proliferation-inducing ligand (“APRIL”) for the potential treatment of autoimmune diseases.
In the company’s own words · 10-K filed Feb 26, 2026 · SEC EDGAR
Business segments
Jun 2026 · $7.6MThe company’s own SEC segment disclosure.
- License Collaboration And Royalty$3.8M50%
- Service$3.8M50%
Aurinia Pharmaceuticals Inc. (AUPH) reported revenue of $78M in Q1 2026 (quarter ended Mar 31, 2026), up 24% from the same quarter a year earlier. That came with a gross margin of 92% and net income of $34M (44% of revenue). For the full year FY2025, revenue was $283M (+20% year on year) and net income $287M. Its largest product in Jun 2026 was License Collaboration And Royalty at $3.8M, 50.1% of the disclosed total, just ahead of Service at 49.9%.
Raw charts
10 series · TTMAs reported to the SEC, without any scoring.